Answers are grounded in this paper and cite their sources.
Subretinal fibrosis (SF) is a vision-threatening complication of neovascular age-related macular degeneration (nAMD) with no effective treatment. Epithelial-mesenchymal transition (EMT) of retinal pigment epithelial (RPE) cells, driven by TGF-β signaling, is a key driver of SF. Sophocarpine (SOP) shows anti-fibrotic potential in other organs, but its role in ocular fibrosis remains unknown. To evaluate SOP’s therapeutic efficacy against SF and elucidate whether it inhibits TGF-β-induced RPE-EMT. Retinal safety of intravitreal SOP was assessed in C57BL/6J mice by electroretinography and histology. A laser-induced choroidal neovascularization (CNV) mouse model was used to evaluate SOP effects on SF in vivo. In vitro, TGF-β1-induced EMT models in ARPE-19 and iPSC-RPE cells were established. EMT markers were analyzed by qPCR, Western blot, and immunofluorescence. Functional assays included wound healing, Transwell migration, and gel contraction. RNA-seq and molecular docking explored mechanisms. Intravitreal SOP (200 µM) showed no detectable acute retinal toxicity. SOP reduced CNV lesion size, collagen deposition, and α-SMA/RPE65 co-localization in laser-induced mice. In vitro, SOP suppressed TGF-β1-induced upregulation of fibronectin, α-SMA, and vimentin, preserved ZO-1, and reduced migration and contraction in RPE cells. Mechanistically, SOP preferentially reduced MEK/ERK and p38 MAPK phosphorylation without affecting Smad2/3. Molecular docking and molecular dynamics simulations predict binding of SOP to MEK1, MEK2, and ERK2. SOP attenuated experimental SF and suppressed TGF-β1-induced EMT-like changes in RPE cells, in association with reduced MEK/ERK and p38 MAPK signaling. SOP represents a promising preclinical candidate that warrants further investigation.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: